+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Advanced Drug Delivery Systems Market - Growth, Trends, and Forecast (2019 - 2024)

  • ID: 4756820
  • Report
  • 110 pages
  • Mordor Intelligence
until Mar 31st 2020
1 of 4


  • 3M
  • Abbott Laboratories
  • Amgen Inc.
  • Astrazeneca
  • Baxter International
  • Bayer Healthcare
  • MORE
Market Overview

The global advanced drug delivery systems market is expected to register a CAGR of 5% during the forecast period, 2019 to 2024. The factors that are driving this market include the development of new drugs and biologics, advancements in understanding human biology and diseases, and increased R&D spending.

The advanced drug delivery systems are more focused on the maintenance of bioavailability of drug as per patient requirement, as well as the rate of drug delivery. Genetic engineering led to the development of new strategies to deliver biotechnologically-derived protein, peptide drugs, and chemoimmunoconjugates. The advanced drugs and biologics have higher efficiency with a smaller dosage of the drug, and hence they have to be supported with advanced drug delivery systems to gain maximum efficacy from the drug. In addition to the drugs and biologics, the drug-eluting implants have the potential to provide uninterrupted treatment and reduction in drug dosage (hence lesser need for frequent dosing). The advanced sustained release systems help target intestinal infections and others.

The increasing disease burden across the world, the proven efficacy of controlled-release drug delivery systems in addressing a wide range of diseases, and the growing R&D trends by both the innovators and the generic players for advanced drug delivery systems, are propelling the growth of the market.

Scope of the Report

The concept of advanced drug delivery system is to increase the efficacy of drugs. Advanced drug delivery systems are adopted to increase the bioavailability of the drug, reduce adverse effects and side effects, and increase drug stability.

Key Market Trends

Oral Drug Delivery System Segment by Type to Hold the Highest CAGR

The oral drug delivery system segment of the global advanced drug delivery systems market is expected to record the highest CAGR over the forecast period.

Over the past decade, the oral controlled-release drug delivery system has received extensive attention, due to its flexibility, reduced dosing frequency, and better patient compliance. The aforementioned factor, in combination with a reasonable cost of oral controlled-release drug delivery system, has led to the ease of market penetration.

North America Dominates the Market and is Believed to Follow the Same Trend Over the Forecast Period

North America currently dominates the advanced drug delivery systems market and is expected to continue its stronghold for a few more years. The United States holds the largest share of this market in the North America region. Advancements in pharmacology and the increasing adoption of a novel drug delivery system are expected to drive the US drug delivery systems market during the forecast period.

Competitive Landscape

The advanced drug delivery systems market is moderately competitive. Some of the major players in this market are Boston Scientific Corporation, Baxter International, 3M, Abbott Laboratories, and GlaxoSmithKline PLC. Owing to the continuous technological advancements in the drug delivery system, there is a possibility of new entrants in the market in the coming future.
Note: Product cover images may vary from those shown
2 of 4


  • 3M
  • Abbott Laboratories
  • Amgen Inc.
  • Astrazeneca
  • Baxter International
  • Bayer Healthcare
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Development of New Drugs and Biologics
4.2.2 Advancements in Understanding Human Biology and Diseases
4.2.3 Increased R&D Spending
4.3 Market Restraints
4.3.1 Product Recalls of Advanced Drug Delivery Products
4.3.2 Challenges in Nanomedicine-based Drug Delivery
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Type
5.1.1 Oral Drug Delivery System
5.1.2 Injection-based Drug Delivery System
5.1.3 Inhalation/Pulmonary Drug Delivery System
5.1.4 Transdermal Drug Delivery System
5.1.5 Trans mucosal Drug Delivery System
5.1.6 Carrier-based Drug Delivery System
5.1.7 Other Types
5.2 By Application
5.2.1 Cardiovascular Diseases
5.2.2 Oncology
5.2.3 Urology
5.2.4 Diabetes
5.2.5 CNS
5.2.6 Ophthalmology
5.2.7 Inflammatory Diseases
5.2.8 Infections
5.2.9 Other Applications
5.3 By Technology
5.3.1 Prodrug
5.3.2 Implants And Intrauterine Devices
5.3.3 Targeted Drug Delivery
5.3.4 Polymeric Drug Delivery
5.3.5 Other Technologies
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
5.4.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 3M
6.1.2 Abbott Laboratories
6.1.3 Amgen Inc.
6.1.4 Astrazeneca
6.1.5 Baxter International
6.1.6 Bayer Healthcare
6.1.7 Boston Scientific Corporation
6.1.8 Glaxosmithkline PLC
6.1.9 Merck & Co.
6.1.10 Novartis AG

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • 3M
  • Abbott Laboratories
  • Amgen Inc.
  • Astrazeneca
  • Baxter International
  • Bayer Healthcare
  • Boston Scientific Corporation
  • Glaxosmithkline PLC
  • Merck & Co.
  • Novartis AG
Note: Product cover images may vary from those shown